Enzymatic variants with improved ester synthase properties

摘要

Variant ester synthase polypeptide comprising SEQ ID NO: 2, wherein said ester synthase variant polypeptide is genetically engineered to have a) a mutation at the amino acid position of SEQ ID NO: 2, or b) the mutation S15G of SEQ ID NO: 2, oc) the S15G mutation and the T5P, P111S, V171R, P188R, F317W, S353T, V409L and S442G mutations of SEQ ID NO: 2, od) the S15G mutation and the T5P, K78F mutations, P111S, V171R, P188R, S192V, A243R, F317W, K349H, S353T, V409L and S442G of SEQ ID NO: 2, oe) mutation S15G and mutations T5P, V76L, P111S, V171R, P188R, K25GR, K25GR S353T, M360R, Y409L and S442G of SEQ ID NO: 2, of) the S15G mutation and the mutations T5P, P111S, V171R, P188R, Q244G, S267G, G310V, F317W, A320C, S353T, Y366Q, V409L and V409L ID2 NO: 2, or g) the S15G mutation and the P111S, V155G, P166S, V171R, P188R, F317W, Q348A, S353T, V381F, V409L and S442G mutations of SEQ ID NO: 2, oh) the S15G mutation and the L39S mutations,D77A, P111S, V171R, P188R, T313S, F317W, Q348A, S353T, V381F, V409L, I420V and S442G of SEQ ID NO: 2, oi) the S15G mutation and the mutations T5P, T24W, T44F, P111S, I17 P188R, D307N, F317W, S353T, V409L and S442G of SEQ ID NO: 2, o) the S15G mutation and T5P mutations, K78F, P111S, V171R, P188R, S192V, R207A, A243R, D255E, L257I, L25QI, L25QI, L25QI H262Q, G265N, A285V, N288D, N289G, F317W, Q348R, S353T, V381F, V409L and S442G of SEQ ID NO: 2, ok) the S15G mutation and the mutations T5P, K78F, P111S, V171R, P188R, P188R, P188R, P188R, P188R, P188R A243R, D255E, L257I, N259Q, L260V, H262Q, G265N, A285V, N288D, N289G, F317W, H349K, S353T, V381F, V409L and S442G of SEQ ID NO: 2, ol) the S15G mutation, G335, G335 T44K, Y58L, P111S, R162E, V171R, P188R, R207A, V234C, Q244G, D255E, S267G, D307N, G310V, F317W, A320C, S353T, 20 Y366W, G394E, V409L and S442G and ID44: ID S15G mutation and T5P, G33D, T44K, Y58C, P111S, V171R, P188R, R207A, V234C, Q244G, L2571, S267G, D307N mutations , G310V, F317W, A320C, S353T, Y366W, G394E, V409L, A413T, I461V and S442G of SEQ ID NO: 2, on) the S15G mutation and the T5P mutations, T44A, P111S, T157S, N164D, T1R, P170S, V1R8 , R207A, V216I, V234C, Q244G, L257I, S267G, D307N, G310V, F317W, A320C, Q334K, S353T, Y366W, G394E, V409L, S442G and I461V of SEQ ID NO: 2, u5G the mutations , Y58L, P111S, R162E, T170S, V171R, A179S, P188R, R207A, V234C, Q244G, L257I, S267G, D307N, G310V, F317W, A320C, S353K, Y366W, G394E, V409, ID402, V409, ID402 , wherein said ester synthase variant polypeptide has enhanced fatty acid methyl ester activity compared to a corresponding wild polypeptide.